AUTHOR: Yaping WANG, Minghong BI,Haoran ZHANG, Zhenyuan GAO, Hairong ZHOU and Shu CHANG

SOURCE: Medicine

 

Abstract
Gastric cancer (GC) is the most common gastrointestinal malignant tumor, with a gradual increasing incidence
throughout the world. Mostly GC is diagnosed in its late stage. To date, there is no usable standardized
treatment regimen for patients with advanced GC. Apatinib mesylate, small-molecule vascular endothelial
growth factor receptor-2 (VEGFR-2) tyrosine kinase inhibitor (TKI), has been approved as third-line
treatment for patients with advanced gastric adenocarcinoma in China, October, 2014. Till now, there is no
case report about apatinib as first-line treatment for patients with advanced GC in literature.We present an
83-year-old Chinese man with advanced gastric adenocarcinoma, who received apatinib as first-line option
and obtained clinical benefit within 2 weeks. The lung metastases disappeared completely and the liver metastases
shrank significantly. The patient’s progression-free survival was 163 days and overall survival was 201
days. This paper reviews and discusses apatinib as a new targeted